In its Q3 FY16 results presentation Mesoblast revealed the Phase III trial of Revascor in CHF cleared its first interim safety analysis; but, following FDA advice, no information was released on surrogate measures of efficacy. Mesoblast and Teva will update the market on timelines for the CHF Phase III programme later this quarter, while RA and GvHD data are expected next quarter. Mesoblast maintained a reduced cash burn of US$22m in Q3, giving it a cash runway to end FY17 on our estimates. O
11 May 2016
CHF Phase III clears interim safety analysis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CHF Phase III clears interim safety analysis
Mesoblast Limited (MSB:ASX) | 0 0 -2.3% | Mkt Cap: 591.5m
- Published:
11 May 2016 -
Author:
Dr Dennis Hulme -
Pages:
3
In its Q3 FY16 results presentation Mesoblast revealed the Phase III trial of Revascor in CHF cleared its first interim safety analysis; but, following FDA advice, no information was released on surrogate measures of efficacy. Mesoblast and Teva will update the market on timelines for the CHF Phase III programme later this quarter, while RA and GvHD data are expected next quarter. Mesoblast maintained a reduced cash burn of US$22m in Q3, giving it a cash runway to end FY17 on our estimates. O